These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 29150430)

  • 1. Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4.
    Mo X; Zhang H; Preston S; Martin K; Zhou B; Vadalia N; Gamero AM; Soboloff J; Tempera I; Zaidi MR
    Cancer Res; 2018 Jan; 78(2):436-450. PubMed ID: 29150430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).
    Fietz S; Zarbl R; Niebel D; Posch C; Brossart P; Gielen GH; Strieth S; Pietsch T; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    Cancer Immunol Immunother; 2021 Jun; 70(6):1781-1788. PubMed ID: 33196890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
    Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
    J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variation in IRF4 expression modulates growth characteristics, tyrosinase expression and interferon-gamma response in melanocytic cells.
    Chhabra Y; Yong HXL; Fane ME; Soogrim A; Lim W; Mahiuddin DN; Kim RSQ; Ashcroft M; Beatson SA; Ainger SA; Smit DJ; Jagirdar K; Walker GJ; Sturm RA; Smith AG
    Pigment Cell Melanoma Res; 2018 Jan; 31(1):51-63. PubMed ID: 28755520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy.
    Juraleviciute M; Nsengimana J; Newton-Bishop J; Hendriks GJ; Slipicevic A
    Cancer Med; 2021 Apr; 10(8):2840-2854. PubMed ID: 33734579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity.
    Herrmann A; Lahtz C; Nagao T; Song JY; Chan WC; Lee H; Yue C; Look T; Mülfarth R; Li W; Jenkins K; Williams J; Budde LE; Forman S; Kwak L; Blankenstein T; Yu H
    Cancer Res; 2017 Sep; 77(18):5118-5128. PubMed ID: 28716895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel stilbene-like compound that inhibits melanoma growth by regulating melanocyte differentiation and proliferation.
    Stueven NA; Schlaeger NM; Monte AP; Hwang SL; Huang CC
    Toxicol Appl Pharmacol; 2017 Dec; 337():30-38. PubMed ID: 29042215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
    Khunger A; Piazza E; Warren S; Smith TH; Ren X; White A; Elliott N; Cesano A; Beechem JM; Kirkwood JM; Tarhini AA
    PLoS One; 2021; 16(1):e0245287. PubMed ID: 33428680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment.
    Li H; Li J; Zhang C; Zhang C; Wang H
    Cancer Med; 2020 Oct; 9(19):7151-7160. PubMed ID: 32810393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.
    Rodríguez T; Méndez R; Del Campo A; Jiménez P; Aptsiauri N; Garrido F; Ruiz-Cabello F
    BMC Cancer; 2007 Feb; 7():34. PubMed ID: 17319941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
    Garcia-Perez JE; Baxter RM; Kong DS; Tobin R; McCarter M; Routes JM; Verbsky J; Jordan MB; Dutmer CM; Hsieh EWY
    Front Immunol; 2019; 10():998. PubMed ID: 31156616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK.
    Sarkar D; Su ZZ; Lebedeva IV; Sauane M; Gopalkrishnan RV; Valerie K; Dent P; Fisher PB
    Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10054-9. PubMed ID: 12114539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma.
    Momtaz S; Niaz K; Maqbool F; Abdollahi M; Rastrelli L; Nabavi SM
    Biofactors; 2017 May; 43(3):347-370. PubMed ID: 27896891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.
    Bresler SC; Min L; Rodig SJ; Walls AC; Xu S; Geng S; Hodi FS; Murphy GF; Lian CG
    Lab Invest; 2017 Feb; 97(2):207-216. PubMed ID: 27918555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.
    Maurus K; Hufnagel A; Geiger F; Graf S; Berking C; Heinemann A; Paschen A; Kneitz S; Stigloher C; Geissinger E; Otto C; Bosserhoff A; Schartl M; Meierjohann S
    Oncogene; 2017 Sep; 36(36):5110-5121. PubMed ID: 28481878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma.
    Gollob JA; Sciambi CJ; Huang Z; Dressman HK
    Cancer Res; 2005 Oct; 65(19):8869-77. PubMed ID: 16204058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab.
    Pistillo MP; Carosio R; Grillo F; Fontana V; Mastracci L; Morabito A; Banelli B; Tanda E; Cecchi F; Dozin B; Gualco M; Salvi S; Spagnolo F; Poggi A; Queirolo P
    Clin Immunol; 2020 Jun; 215():108428. PubMed ID: 32344017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas.
    Hoek K; Rimm DL; Williams KR; Zhao H; Ariyan S; Lin A; Kluger HM; Berger AJ; Cheng E; Trombetta ES; Wu T; Niinobe M; Yoshikawa K; Hannigan GE; Halaban R
    Cancer Res; 2004 Aug; 64(15):5270-82. PubMed ID: 15289333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic melanoma cells evade immune detection by silencing STAT1.
    Osborn JL; Greer SF
    Int J Mol Sci; 2015 Feb; 16(2):4343-61. PubMed ID: 25690042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.
    Dovhey SE; Ghosh NS; Wright KL
    Cancer Res; 2000 Oct; 60(20):5789-96. PubMed ID: 11059775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.